|Go to market news section|
SkyePharma (Jersey) Limited - Publication of Prospectus
LONDON, UK, 30 November 2012 - SkyePharma PLC (LSE: SKP) announces that SkyePharma (Jersey) Limited has today published a prospectus in order to effect the listing of its £14,764,007 6.5 per cent. Guaranteed Bonds due 2024, which were issued on 24 September 2012.
A copy of the prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do
For further information, please contact:
Peter Grant, Chief Executive Officer +44 207 881 0524
Jonathan Birt /Julia Phillips/Susan Stuart +44 207 831 3113
Using its multiple drug delivery technologies and expertise, SkyePharma creates enhanced versions of pharmaceutical products. The Group receives revenues from thirteen approved products in the areas of inhalation, oral, topical and injectable delivery as well as generating income from the development of further products and technology licenses. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
|©London Stock Exchange plc. All rights reserved|